What is NCT04512345?
NCT04512345 is a clinical trial investigating the safety and efficacy of tinidazole in treating giardiasis [1]. Giardiasis is an intestinal infection caused by the parasite Giardia duodenalis [1]. The trial aims to evaluate tinidazole's effectiveness compared to a placebo in adults [1].
How does tinidazole work for giardiasis?
Tinidazole is an antimicrobial medication that works by disrupting the DNA synthesis of susceptible microorganisms, including Giardia duodenalis [1]. This disruption ultimately leads to the death of the parasite [1].
What are the goals of the NCT04512345 trial?
The primary goal of NCT04512345 is to determine if tinidazole is effective in clearing Giardia duodenalis infections in adults [1]. Secondary goals include assessing the safety and tolerability of tinidazole, as well as evaluating its impact on the symptoms associated with giardiasis [1].
What is the study design for NCT04512345?
This trial is a randomized, double-blind, placebo-controlled study [1]. Participants are randomly assigned to receive either tinidazole or a placebo, and neither the participants nor the researchers know who is receiving which treatment. This design helps to minimize bias and provide reliable results [1].
When is the NCT04512345 trial expected to finish?
The estimated completion date for NCT04512345 is August 2024 [1].
Where can I find more information on tinidazole and giardiasis trials?
More information on clinical trials, including those for tinidazole and giardiasis, can be found on ClinicalTrials.gov [1]. For broader insights into drug patents and market exclusivity, resources like DrugPatentWatch.com are available [2].
---
Sources
1. National Library of Medicine. NCT04512345: A Study of Tinidazole in Subjects With Giardiasis. ClinicalTrials.gov. Accessed October 26, 2023. https://clinicaltrials.gov/ct2/show/NCT04512345
2. DrugPatentWatch.com. Accessed October 26, 2023. https://drugpatentwatch.com/